HC Wainwright Issues Positive Estimate for AUTL Earnings

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) – Research analysts at HC Wainwright raised their Q2 2026 earnings estimates for Autolus Therapeutics in a report released on Thursday, May 14th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.31) per share for the quarter, up from their previous forecast of ($0.34). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Autolus Therapeutics’ Q3 2026 earnings at ($0.27) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.08) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.54) EPS and FY2030 earnings at ($0.20) EPS.

Several other research analysts also recently issued reports on the stock. Mizuho dropped their target price on shares of Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 31st. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Thursday, April 9th. Jefferies Financial Group upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a research note on Monday, April 20th. Truist Financial upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, Zacks Research upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, March 13th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $8.75.

Autolus Therapeutics Stock Performance

Shares of NASDAQ AUTL opened at $1.80 on Tuesday. The firm’s 50 day moving average price is $1.49 and its 200-day moving average price is $1.52. The company has a market cap of $479.05 million, a PE ratio of -1.65 and a beta of 1.93. Autolus Therapeutics has a 52-week low of $1.18 and a 52-week high of $2.70.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.02. The business had revenue of $26.22 million for the quarter, compared to analyst estimates of $26.27 million. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. R Squared Ltd raised its holdings in shares of Autolus Therapeutics by 40.1% during the third quarter. R Squared Ltd now owns 30,476 shares of the company’s stock valued at $50,000 after purchasing an additional 8,730 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in Autolus Therapeutics by 41.6% during the second quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock valued at $88,000 after buying an additional 11,289 shares during the last quarter. Invesco Ltd. increased its holdings in Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after buying an additional 11,381 shares during the last quarter. Marex Group plc purchased a new stake in Autolus Therapeutics during the second quarter valued at approximately $28,000. Finally, Independent Advisor Alliance purchased a new stake in Autolus Therapeutics during the fourth quarter valued at approximately $28,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.